Background/Objectives: Non-ablative local therapies are increasingly used in the conservative management of human papillomavirus (HPV) infection. Coriolus versi-color, an immunomodulatory medicinal mushroom, is one such approach. This study aimed to investigate the effect of a Coriolus versicolor–based vaginal gel on HPV clearance and cervical cytological outcomes. Methods: This retrospective cohort study included 600 women with cervical HPV infection (300 treated with a Coriolus versi-color–based vaginal gel and 300 receiving standard follow-up). Baseline and six-month follow-up assessments included HPV DNA testing and cervical cytology. Results: Baseline demographic characteristics, HPV genotype distribution, and cytological findings were comparable between the groups. Overall HPV clearance was signifi-cantly higher in the treatment group than in the control group (89.3% vs. 44.7%, p < 0.001). Complete clearance of high-risk HPV genotypes, including HPV 16 (77.0% vs. 25.4%, p < 0.001) and HPV 18 (73.9% vs. 18.5%, p = 0.017), was also significantly more frequent among treated women. Cytological normalization occurred more often in the treatment group (88.4% vs. 60.4%, p < 0.001). Multivariable analysis identified use of the vaginal gel as the strongest independent factor associated with HPV clearance (adjusted odds ratio [aOR] = 8.45; 95% confidence interval [CI]: 3.05–23.43; p < 0.001). Conclusions: Treatment with a Coriolus versicolor–based vaginal gel was associated with significantly higher rates of high-risk HPV clearance and cervical cytological normalization. These findings suggest that this therapy may represent an effective ad-junct in the conservative management of HPV infection; however, randomized con-trolled trials are warranted to confirm these results.

Introduction: Chemotherapy response score (CRS) is a prognostic marker in high-grade serous ovarian carcinoma treated with neoadjuvant chemotherapy (NACT). This study evaluated whether the survival benefit associated with sustained bevacizumab exposure differs according to CRS group. Methods: We retrospectively evaluated patients who underwent interval debulking surgery after platinum-taxane-based NACT between January 2015 and February 2025. Sustained bevacizumab exposure was defined as receipt of more than three cycles. Overall survival (OS) and OS after first recurrence (OS-FR) were assessed using Kaplan–Meier and Cox regression analyses. Results: The cohort included 113 patients: 30 with sustained bevacizumab exposure and 83 in the comparison group; 74 had CRS 1–2 and 39 had CRS 3. Sustained bevacizumab was associated with longer median OS in the overall cohort (57.4 vs. 50.3 months; p = 0.021) and in patients with CRS 1–2 (57.1 vs. 43.6 months; p = 0.045), but not in those with CRS 3 (p = 0.224). OS-FR was also longer with sustained bevacizumab overall (35.0 vs. 23.0 months; p = 0.013) and in CRS 1–2 (35.0 vs. 23.0 months; p = 0.041). In multivariable analysis, sustained bevacizumab was independently associated with improved OS-FR (landmark-corrected HR 0.23, 95% CI 0.07–0.75; p = 0.015). Conclusions: Sustained bevacizumab exposure was associated with longer OS and OS-FR, particularly in patients with CRS 1–2. CRS may help identify patients most likely to benefit from bevacizumab, although these findings require prospective validation.

Background: Persistent cervical human papillomavirus (Human papillomavirus) infection remains a significant public health concern, as it is the primary etiological factor in the development of cervical cancer and its precursor lesions. While prophylactic vaccination and standard screening programs are cornerstones of prevention, a substantial proportion of women with established infection are managed conservatively, often with prolonged follow-up and associated psychological burden. Interest has therefore grown in supportive interventions that may facilitate viral clearance during routine clinical management. Methods: This retrospective cohort study included 239 women with confirmed cervical Human papillomavirus infection followed at a tertiary referral center between February 2023 and August 2025. Participants were classified into a treatment group receiving oral Papivir/Pavirona^® twice daily for six months (n = 119) and a control group managed with routine clinical follow-up alone (n = 120). Human papillomavirus DNA testing and cervical cytology were evaluated at baseline and at 6 and 12 months. Results: Human papillomavirus clearance rates were significantly higher in the Papivir/Pavirona^® group compared with controls at both 6 and 12 months. Cytological regression was also more frequent in the treatment group at both time points. In multivariate logistic regression analysis, Papivir/Pavirona^® use emerged as the only independent predictor of both Human papillomavirus clearance and cytological regression, while demographic, reproductive, behavioral, and virological baseline characteristics were not significantly associated with outcomes. Conclusions: Papivir/Pavirona^® supplementation was associated with increased Human papillomavirus clearance and cytological regression rates in women with cervical Human papillomavirus infection, suggesting a potential supportive role alongside standard clinical follow-up.

Background/Objectives: Non-ablative local therapies are increasingly used in the conservative management of human papillomavirus (HPV) infection. Coriolus versicolor, an immunomodulatory medicinal mushroom, is one such approach. This study aimed to investigate the effect of a Coriolus versicolor–based vaginal gel on HPV clearance and cervical cytological outcomes. Methods: This retrospective cohort study included 600 women with cervical HPV infection (300 treated with a Coriolus versicolor–based vaginal gel and 300 receiving standard follow-up). Baseline and six-month follow-up assessments included HPV DNA testing and cervical cytology. Results: Baseline demographic characteristics, HPV genotype distribution, infection type, and cytological findings were comparable between the groups. Overall HPV clearance was significantly higher in the treatment group than in the controls (89.3% vs. 44.7%, p < 0.001). Complete clearance of high-risk HPV genotypes, including HPV 16 (77.0% vs. 25.4%, p < 0.001) and HPV 18 (73.9% vs. 18.5%, p = 0.017), was also significantly more frequent among treated women. Cytological normalization occurred more often in the treatment group (88.4% vs. 60.4%, p < 0.001). Multivariable analysis identified use of the vaginal gel as the strongest independent factor associated with HPV clearance (adjusted odds ratio [aOR] = 10.19; 95% confidence interval [CI]: 3.52–29.47; p < 0.001). Conclusions: Treatment with a Coriolus versicolor–based vaginal gel was associated with significantly higher rates of high-risk HPV clearance and cervical cytological normalization. These findings suggest that this therapy may represent an effective adjunct in the conservative management of HPV infection; however, randomized controlled trials are warranted to confirm these results.

Objective:To evaluate the effects of Papivir/Pavirona® tablets, containing cinnamon extract, selenium, quercetin, licorice root, and green tea extract, on cervical human papillomavirus (HPV) clearance and cytological outcomes in women with cervical HPV infection. Methods: This retrospective cohort study included 239 women with con-firmed cervical HPV infection, followed at a tertiary referral center between February 2023 and August 2025. Participants were classified into a treatment group receiving oral Papivir/Pavirona® twice daily for six months (n = 119) and a control group managed with routine clinical follow-up alone (n = 120). HPV DNA testing and cervical cytology were evaluated at baseline and during follow-up visits at 6 and 12 months. Results: HPV clearance rates were significantly higher among Papivir/Pavirona® users at both 6 and 12 months compared with controls (67.2% vs. 29.2% and 69.1% vs. 46%, respectively). Cytological regression was also more frequent in the Papivir/Pavirona® group at 6 months (81.1% vs. 54.5 %) and 12 months (77.9% vs. 52.8%). In multivariate logistic re-gression analysis, Papivir/Pavirona® use emerged as an independent predictor of both HPV clearance and cytological regression, whereas demographic, reproductive, behav-ioral, and virological baseline characteristics were not significantly associated with outcomes. Conclusions: It has been suggested that Papivir/Pavirona® supplementation is associated with increased HPV clearance and cytological regression rates in women with cervical HPV infection, and may play a potential supportive role in cervical HPV management.